Our Recommendations
- Временные рекомендации по использованию вакцины BNT162b2, COVID-19, Pfizer - BioNTech, в соответствии с перечнем препаратов для применения в чрезвычайных ситуациях (2021)
- Beschluss der STIKO zur 19. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung (2022)
- Recommandations provisoires pour l’utilisation du vaccin anti-COVID-19 Pfizer-BioNTech, BNT162b2, en vertu du protocole OMS d’autorisation d’utilisation d’urgence (2022)
- Recomendaciones provisionales para utilizar la vacuna contra la COVID-19 elaborada por Pfizer y BioNTech, BNT162b2, en el marco de la lista de uso en emergencias: orientaciones provisionales, 8 de ene (2021)
- Временные рекомендации по использованию вакцины BNT162b2, COVID-19, Pfizer - BioNTech, в соответствии с перечнем препаратов для применения в чрезвычайных ситуациях: временные рекомендации от 8 января (2021)
New Publications
- Good practice statement on the use of variant-containing COVID-19 vaccines (2022)
- Recomendações provisórias para o uso da vacina Pfizer-BioNTech COVID-19, BNT162B2, na lista de uso de emergência. Orientação provisória 21 de janeiro de 2022 (2022)
- Operational guidance on establishing an ultra-cold chain system in support of the Pfizer-BioNTech COVID-19 vaccine rollout, 1 February 2022 (2022)
- Recommandations provisoires pour l’utilisation du vaccin anti-COVID-19 Pfizer-BioNTech, BNT162b2, en vertu du protocole OMS d’autorisation d’utilisation d’urgence (2022)
- Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing (2022)
Filter
23
Featured
Recommendations
6
Language
Document type
Guidelines
15
Studies & Reports
3
Fact sheets
3
Manuals
2
Countries / Regions
Germany
2
Argentina
2
Brazil
2
Russia
2
Kazakhstan
1
Mozambique
1
Global
1
Latin America and the Carribbean
1
Belarus
1
Authors & Publishers
Publication Years
Category
COVID-19
7
Guidelines
3
Policies
1
Women & Child Health
1
Toolboxes
Declarations of interests were collected from all external contributors and assessed for any conflicts of interest. Summaries of the reported interests can be found on the SAGE meeting website and SAGE Covid-19 Working Group webpage. This guidance should be considered along with the broader COVID-...
Bisher hat die STIKO empfohlen, dass alle im Ausland mit einem nicht in der EU zugelassenen Impfstoff geimpften Personen eine erneute Impfserie mit einem in der EU zugelassenen Impfstoff erhalten sollen. Ziel der im Epidemiologischen Bulletin 13/2022 veröffentlichten aktualisierten COVID-19-Impfemp...
orientations provisoires, première publication : 8 janvier 2021, mise à jour : 15 juin 2021, mise à jour : 19 novembre 2021, mise à jour : 21 janvier 2022
These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
fir...
updated version: 04/10/2021
Information about vaccine administration
Временное руководство, Первый выпуск 8 января 2021 г., Обновлено 15 июня 2021 г., Обновлено 19 ноября 2021 г.
Training on handling, storing and transporting Pfizer BioNTech COVID-19 Vaccine COMIRNATY® (Tozinameran)
recommended
4 August 2021. Currently, Pfizer BioNTech COVID-19 Vaccine COMIRNATY® (Tozinameran) is the only COVID-19 vaccine that should be stored and transported at -60ºC to -86ºC ultra-low temperature (ULT) conditions. Prior to use the vaccine can be transferred to -20ºC freezer or +2-8ºC refrigerator at...
временные рекомендации от 8 января 2021 г.
Available in Arabic, Chinese, English, French, Russian and Spanish here: https://apps.who.int/iris/handle/10665/338484
